These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 8043944)
1. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Fitton A; Brogden RN Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944 [TBL] [Abstract][Full Text] [Related]
2. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750 [TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854 [TBL] [Abstract][Full Text] [Related]
4. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Hagemeijer F Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722 [TBL] [Abstract][Full Text] [Related]
5. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan. Kubo SH Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743 [No Abstract] [Full Text] [Related]
6. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?]. Rasmussen T; Schmidt H Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807 [TBL] [Abstract][Full Text] [Related]
7. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695 [TBL] [Abstract][Full Text] [Related]
8. Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. Tsuda T; Izumi T; Kodama M; Hanawa H; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Kuwano H; Shibata A Jpn Heart J; 1992 Mar; 33(2):193-203. PubMed ID: 1593749 [TBL] [Abstract][Full Text] [Related]
9. A review of the pharmacology and clinical uses of pimobendan. Boyle KL; Leech E J Vet Emerg Crit Care (San Antonio); 2012 Aug; 22(4):398-408. PubMed ID: 22928748 [TBL] [Abstract][Full Text] [Related]
10. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy]. Permanetter B; Sebening H; Busch U; Lutilsky L Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013 [TBL] [Abstract][Full Text] [Related]
11. Use of pimobendan in the management of heart failure. Fuentes VL Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517 [TBL] [Abstract][Full Text] [Related]
13. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811 [TBL] [Abstract][Full Text] [Related]
14. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Kubo SH Cardiology; 1997; 88 Suppl 2():21-7. PubMed ID: 9142432 [TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130 [TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. Kato K Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433 [TBL] [Abstract][Full Text] [Related]
17. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Chu KM; Shieh SM; Hu OY Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260 [TBL] [Abstract][Full Text] [Related]
19. Hemodynamic profile of the cardiotonic agent pimobendan. van Meel JC; Diederen W J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784 [TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. Hamabe L; Kawamura K; Kim SM; Yoshiyuki R; Fukayama T; Shimizu M; Fukushima R; Tanaka R J Pharmacol Sci; 2014; 124(3):386-93. PubMed ID: 24599141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]